Evidence map›Paper›PMID 37760408›Full record

ArticleCancers2023

Management of Small Bowel Neuroendocrine Tumours: 10 Years' Experience at a Tertiary Referral Centre.

Ashley K Clift, Panagiotis Drymousis, Alexander von Roon, Adam Humphries, Robert Goldin, Jamshed Bomanji, Sydney Leaman, Harpreet Wasan, Nagy Habib, Andrea Frilling

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Ileal neuroendocrine tumors: clinicopathological features and associations with systemic inflammatory and nutritional markers.Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 1 country.

Ashley K CliftDepartment of Surgery and Cancer, Imperial College London, Hammersmith Campus, Du Cane Road, London W12 0HS, UK.
Panagiotis DrymousisDepartment of Surgery, Ealing Hospital, London North West University Healthcare NHS Trust, London HA1 3UJ, UK.
Alexander von RoonDepartment of Surgery, University College London Hospitals NHS Foundation Trust London, London NW1 2BU, UK.
Adam HumphriesDepartment of Gastroenterology, St Mark's Hospital, London North West University Health Care NHS Trust, London HA1 3UJ, UK.
Robert GoldinDepartment of Surgery and Cancer, Imperial College London, Hammersmith Campus, Du Cane Road, London W12 0HS, UK.
Jamshed BomanjiDepartment of Nuclear Medicine, University College London Hospitals NHS Foundation Trust London, London NW1 2BU, UK.
Sydney LeamanMRC Centre for Neurodevelopmental Disorders, King's College London, London SE1 8WA, UK.
Harpreet WasanDepartment of Surgery and Cancer, Imperial College London, Hammersmith Campus, Du Cane Road, London W12 0HS, UK.
Nagy HabibDepartment of Surgery and Cancer, Imperial College London, Hammersmith Campus, Du Cane Road, London W12 0HS, UK.ORCID 0000-0003-4920-4154
Andrea FrillingDepartment of Surgery and Cancer, Imperial College London, Hammersmith Campus, Du Cane Road, London W12 0HS, UK.ORCID 0000-0001-6130-2035
Imperial College London · GBUniversity College London Hospitals NHS Foundation Trust · GBEaling Hospital · GBKing's College London · GBLondon North West Healthcare NHS Trust · GBUniversity of Oxford · GB

Funding

European Union FP7 PDHeinz Horst Deichmann Foundation HHDF1
6 · The paper itself

Abstract

backgroundNeuroendocrine tumours (NET) arising from the small bowel are clinically challenging and are often diagnosed at advanced stages. Disease control with surgery alone can be demanding. Multimodal treatment concepts integrating surgery and non-surgical modalities could be of benefit.

methodRetrospective review of consecutive adult patients with SB NET treated at Imperial College Healthcare NHS Trust between 1 January 2010 and 31 December 2019. Data regarding clinicopathological characteristics, treatments, and disease trajectory were extracted and summarised. Overall and progression/recurrence-free survival were estimated at 5 and 10 years.

results154 patients were identified, with a median age of 64 years (range 33-87); 135/154 (87.7%) had stage III/IV disease at diagnosis. Surgery was used in 125 individuals (81.2%), typically with either segmental small bowel resection (60.8%) or right hemicolectomy (33.6%) and mesenteric lymphadenectomy for the primary tumour. Systemic and/or liver-directed therapies were used in 126 (81.8%); 60 (47.6%) had more than one line of non-surgical treatment. Median follow-up was 67.2 months (range 3.1-310.4); overall survival at 5 and 10 years was 91.0% (95% CI: 84.9-94.7%) and 82.5% (95% CI: 72.9-88.9%), respectively. Imaging-based median progression-free survival was 42.7 months (95% CI: 24.7 to 72.4); 5-year progression-free survival was 63.4% (95% CI: 55.0-70.6%); 10-year progression-free survival was 18.7% (95% CI: 12.4-26.1). Nineteen patients (12.3%) reached 10 years follow-up without disease recurrence and therefore were considered cured.

conclusionsMost patients with SB NET present in a metastasised stage. Multimodal treatment concepts may be associated with excellent clinical outcomes. Future work should explore optimal approaches to treatment sequencing and patient selection.

Indexed as

multimodal treatmentneuroendocrinesmall intestinesurgery

Identifiers

PMID37760408
PMCPMC10526159
OpenAlexW4386484888

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.